{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-040650","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.889058+00:00","generated_at":"2026-05-31T05:39:29.452332+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roivant unveils mosliciguat, inhaled sGC activator for PH-ILD; Phase 1b shows PVR reduction up to 38%","bullets":["Phase 1b ATMOS in 38 PH patients: single dose of mosliciguat produced mean-max PVR reduction up to ~38%, exceeding ≥20% threshold.","Mosliciguat is potential first-in-class, inhaled once-daily sGC activator with targeted lung delivery via dry powder inhaler.","Global Phase 2 PHocus study in ~120 PH-ILD patients imminent; PH-ILD prevalence ~200,000 in US/Europe with few treatments.","Roivant in-licensed from Bayer for ~$14M upfront, up to $280M milestones + tiered high-single digit royalties.","Favorable safety in 170 participants; 40-hour half-life enables once-daily dosing; differentiated from existing therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-040650","json":"https://secwatch.observer/filing/0001140361-24-040650.json","markdown":"https://secwatch.observer/filing/0001140361-24-040650.md","text":"https://secwatch.observer/filing/0001140361-24-040650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124040650/0001140361-24-040650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124040650/ef20035693_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:39:29.452332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}